Treatment with VIDAZA® initiated at diagnosis significantly increases overall survival in patients with intermediate-2 and high-risk MDSa compared with CCR.1 Learn how early treatment with VIDAZA® reduces transfusion burden, delays AML progression and leads to marked improvement in overall survival.Learn more
Home > Myelodysplastic syndromes (MDS)
VIDAZA® Treatment for MDSa
VIDAZA® is the first drug treatment to significantly prolong overall survival in higher-risk MDS patients and alter the natural history of the disease.1
I am a prescriber of VIDAZA® seeking tips for successful treatment
Learn more about the proper dosing and administration of VIDAZA® >
I am considering VIDAZA® for my patient and am seeking efficacy data
Learn more about the efficacy and potential benefits of VIDAZA® for patients with MDSa >
I am interested in clinical trial information and seeking informational resources
Learn more about the results of two clinical studies investigating VIDAZA® >
- I need dosing & administration tips for patients I treat with VIDAZA® for MDSa.
- I am interested in VIDAZA® clinical trial results in MDSa.
- I want to learn more about MDS.
- I am seeking safety and side effects information for VIDAZA® for MDSa.
- I want to know when to begin treatment with VIDAZA® for MDSa.
- Should I continue treatment with VIDAZA® for my MDSa patients.
- I want to learn more about the efficacy of VIDAZA® for patients with MDSa.
- Fenaux P et al. Lancet Oncology 2009. 10:223-232.
- VIDAZA® Summary of Product Characteristics, 2011.
- Seymour JF et al. Crit Rev Oncol Hematol 2010 76: 218-227.
a. MDS-specific Indication
VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:
- intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
- chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
b. AML-specific Indication:
Treatment of adult AML patients who are not eligible for haematopoietic stem cell transplantation with 20-30% blasts and multi-lineage dysplasia, according to the WHO classification. WHO classifies RAEB-T patients with blasts ?20% to <30% as AML patients.
This is an international website for VIDAZA® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
The information on this website is based on the European Summary of Product Characteristics (SmPC). Please refer to your country-specific website, or contact a Celgene representative in your country for the latest information specific to your country.